Search results for "Janus Kinase Inhibitors"

showing 3 items of 3 documents

Emerging drugs for the treatment of vitiligo.

2020

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treat…

MAP Kinase Signaling SystemAdministration TopicalVitiligoAdministration OralVitiligoBiologicsBioinformatics030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineClinical Trials Phase II as TopicLocalized vitiligoMedicineHumansJanus Kinase InhibitorsPharmacology (medical)skin and connective tissue diseasesRandomized Controlled Trials as TopicPharmacologytreatmentintegumentary systembusiness.industrymedicine.diseaseCombined Modality TherapyJAK inhibitorchemistryClinical Trials Phase III as Topic030220 oncology & carcinogenesisCytokinesAfamelanotideDermatologic AgentsbusinessJanus kinaseBiologics; JAK inhibitor; treatment; vitiligoExpert opinion on emerging drugs
researchProduct

Pharmacology and safety of tofacitinib in ulcerative colitis.

2020

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC). It is a small synthetic molecule administered orally, with a fast bioavailability and elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of tofacitinib and its safety profile.

Moderate to severePharmacologyHerpes ZosterArthritis Rheumatoid03 medical and health sciences0302 clinical medicineImmune systemPharmacokineticsPiperidinesNeoplasmsMedicineHerpes Zoster VaccineHumansJanus Kinase InhibitorsDrug InteractionsTofacitinibbusiness.industryImmunogenicityJanus Kinase 3Janus Kinase 1Venous Thromboembolismmedicine.diseaseUlcerative colitisBioavailabilityPyrimidines030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeJanus kinasebusinessGastroenterologia y hepatologia
researchProduct

Psoriatic arthritis and COVID ‐19 pandemic: Consequences in medical treatment?

2020

The COVID‐19 pandemic has a strong negative impact on human society world‐wide. Patients with immune‐mediated disease may be prone to an increased risk of infection and/ or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID‐19 the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID‐19? Does systemic medical treatment pose an increased risk of infection with SARS‐CoV‐2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis ‐ a factor with strong negativ…

Special Issue Articlesmedicine.medical_specialtyDiseaseComorbidityDermatologyPlacebo030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisPsoriatic arthritis; systemic medical treatment0302 clinical medicinePharmacotherapyCOVID‐19Internal medicinePandemicmedicineHumansJanus Kinase InhibitorsbiologicsBiological Productsbusiness.industrySARS-CoV-2Tumor Necrosis Factor-alphaArthritis PsoriaticInterleukinSpecial Issue ArticleCOVID-19General Medicinemedicine.diseaseComorbiditysmall molecules030220 oncology & carcinogenesisAirwaybusinessDermatologic Therapy
researchProduct